In the NLRC4-Macrophage Activation Syndrome (NLRC4-MAS)/Neonatal-Onset Multisystem Inflammatory Disease (NOMID) cohort (GSE57253), the enrichment score of Group 1 was significantly higher in the disease group than in controls (p = 0.04), closely aligning with the clinical pyroptotic state (Figure 1C). This evidence concerns the gene NLRC4 and macrophage activation syndrome.